Entrada Therapeutics, Inc. (TRDA) — Financial statements
Income statement, balance sheet, and cash flow for Entrada Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 25↓87.9% | 211↑63.4% | 129 | 0.00 | 0.00 | |
| Cost of Revenue | 4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 21↓89.9% | 211↑63.4% | 129 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 142↑13.5% | 125↑25.5% | 100↑50.0% | 67↑85.4% | 36 | |
| General & Administrative Expenses | 41↑6.7% | 38↑19.1% | 32↑5.4% | 31↑101.6% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 41↑6.7% | 38↑19.1% | 32↑5.4% | 31↑101.6% | 15 | |
| Other Expenses | -6 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 177↑8.3% | 164↑23.9% | 132↑35.9% | 97↑90.2% | 51 | |
| Total Costs & Expenses | 181↑10.8% | 164↑23.9% | 132↑35.9% | 97↑90.2% | 51 | |
| Operating Results | ||||||
| Operating Income | -156↓431.8% | 47↑1586.7% | -3↑96.7% | -97↓90.2% | -51 | |
| Depreciation & Amortization | 0.43↓88.7% | 4↑32.8% | 3↑49.9% | 2↑69.7% | 1 | |
| EBITDA | -142↓380.4% | 51↑15920.6% | -0.32↑99.7% | -95↓90.7% | -50 | |
| EBIT | -143↓403.8% | 47↑1586.7% | -3↑96.7% | -97↓90.2% | -51 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 19↑28.0% | 15 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 19↑28.0% | 15↑478.2% | 3 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 3 | 0.00 | |
| Non-Operating Income | -13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 13↓32.4% | 19↑28.0% | 15↑478.2% | 3↑8590.3% | -0.03 | |
| Income Before Tax | -143↓314.8% | 66↑451.5% | 12↑112.7% | -95↓84.9% | -51 | |
| Income Tax Expense | 0.92↑7.6% | 0.86↓95.4% | 19 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -144↓319.0% | 66↑1081.7% | -7↑92.9% | -95↓84.9% | -51 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -144↓319.0% | 66↑1081.7% | -7↑92.9% | -95↓84.9% | -51 | |
| Bottom-Line Net Income | -144↓319.0% | 66↑1081.7% | -7↑92.9% | -95↓84.9% | -51 | |
| EPS (Basic) | -3.47↓297.2% | 1.76↑980.0% | -0.20↑92.8% | -2.79↓74.4% | -1.60 | |
| EPS (Diluted) | -3.47↓306.5% | 1.68↑940.0% | -0.20↑92.8% | -2.79↓74.4% | -1.60 | |
| Weighted Average Shares | 41↑10.9% | 37↑12.9% | 33↑5.6% | 31↑0.2% | 31 | |
| Weighted Average Diluted Shares | 41↑6.1% | 39↑18.0% | 33↑5.6% | 31↑0.2% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.